Updated 10/31/2015:Letter to the community: October 30, 2025REGENXBIO announced that they have completed enrollment in the Phase 1/2 portion of their RGX-202 microdystrophin gene therapy trial, with topline data expected […]
Updated: December 4, 2025 From Belief to Breakthrough: Celebrating Avidity’s Potential Acquisition by Novartis In 2018, CureDuchenne made a bold investment in a promising company with an idea that could […]
Italfarmaco issues a letter to address the recent online discussions about the individuals who have passed away while being treated with Duvyzat (givinostat), confirming that they have determined the deaths […]
CureDuchenne and Andreas S. Barth, MD, PhD, FAHA, for a community webinar about Optimizing Cardiac Outcomes in Duchenne. Watch HERE
Avidity reports multiple functional improvements with Del-zota for individuals with Duchenne amenable to skipping exon 44. Watch HERE
A Fireside Chat with Mike Kelly and Edgewise Therapeutics: A Duchenne Program Update Wednesday, September 3, 2025 WATCH HERE
Limited-Edition Violent Gentlemen Hockey Club Tees Benefiting the CureDuchenne. Your purchase makes a difference.Every tee supports CureDuchenne’s mission to improve the lives of everyone affected by Duchenne muscular dystrophy—by accelerating […]
Results published in the Annals of Clinical and Translational Neurology show that long-term treatment with givinostat, a histone deacetylase (HDAC) inhibitor, in combination with corticosteroids, delayed disease progression in ambulant individuals with […]
